These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 23519822

  • 1. Treatment of primary chronic glomerulonephritis with Rehmannia glutinosa acteosides in combination with the angiotensin receptor blocker irbesartan: a randomized controlled trial.
    Qiu H, Fu P, Fan W, Zuo C, Feng P, Shi P, Cao L, Liu F, Zhou L, Chen F, Zhong H, Gou Z, Liang Y, Shi M.
    Phytother Res; 2014 Jan; 28(1):132-6. PubMed ID: 23519822
    [Abstract] [Full Text] [Related]

  • 2. General acteoside of Rehmanniae leaves in the treatment of primary chronic glomerulonephritis: a randomized controlled trial.
    Qiu H, Fan W, Fu P, Zuo C, Feng P, Liu F, Zhou L, Chen F, Zhong H, Liang Y, Shi M.
    Afr J Tradit Complement Altern Med; 2013 Jan; 10(4):109-15. PubMed ID: 24146510
    [Abstract] [Full Text] [Related]

  • 3. Effects of irbesartan on inflammatory cytokine concentrations in patients with chronic glomerulonephritis.
    Tsuruoka S, Kai H, Usui J, Morito N, Saito C, Yoh K, Yamagata K.
    Intern Med; 2013 Jan; 52(3):303-8. PubMed ID: 23370736
    [Abstract] [Full Text] [Related]

  • 4. [IRMA-pRAcs: irbesartan in the treatment of microalbuminuria and proteinuria in patients with type 2 diabetes and hypertension-prospective observational study involving 38,016 patients in the general practice setting].
    Lehnert H, Bramlage P, Pittrow D, Kirch W.
    MMW Fortschr Med; 2003 Oct 09; 145 Suppl 3():81-7. PubMed ID: 15490772
    [Abstract] [Full Text] [Related]

  • 5. Dual blockade of the rennin-angiotensin system versus maximal recommended dose of angiotensin II receptor blockade in chronic glomerulonephritis.
    Mori-Takeyama U, Minatoguchi S, Murata I, Fujiwara H, Ozaki Y, Ohno M, Oda H, Ohashi H.
    Clin Exp Nephrol; 2008 Feb 09; 12(1):33-40. PubMed ID: 18175062
    [Abstract] [Full Text] [Related]

  • 6. [Effect of irbesartan in proteinuric non-diabetic renal disease].
    de Gracia MC, Molina M, Navarro MJ, Garcia Hernández MA.
    Nefrologia; 2005 Feb 09; 25(5):509-14. PubMed ID: 16392300
    [Abstract] [Full Text] [Related]

  • 7. Treatment of diabetic nephropathy with angiotensin II receptor antagonist.
    Lewis EJ, Lewis JB.
    Clin Exp Nephrol; 2003 Mar 09; 7(1):1-8. PubMed ID: 14586737
    [Abstract] [Full Text] [Related]

  • 8. Effect of dual blockade of the renin-angiotensin system on the progression of type 2 diabetic nephropathy: a randomized trial.
    Fernandez Juarez G, Luño J, Barrio V, de Vinuesa SG, Praga M, Goicoechea M, Cachofeiro V, Nieto J, Fernández Vega F, Tato A, Gutierrez E, PRONEDI Study Group.
    Am J Kidney Dis; 2013 Feb 09; 61(2):211-8. PubMed ID: 22939518
    [Abstract] [Full Text] [Related]

  • 9. Angiotensin blockade and progressive loss of kidney function in hemodialysis patients: a randomized controlled trial.
    Kjaergaard KD, Peters CD, Jespersen B, Tietze IN, Madsen JK, Pedersen BB, Novosel MK, Laursen KS, Bibby BM, Strandhave C, Jensen JD.
    Am J Kidney Dis; 2014 Dec 09; 64(6):892-901. PubMed ID: 25011693
    [Abstract] [Full Text] [Related]

  • 10. A comparison of the efficacy and safety of irbesartan/HCTZ combination therapy with irbesartan and HCTZ monotherapy in the treatment of moderate hypertension.
    Neutel JM, Franklin SS, Lapuerta P, Bhaumik A, Ptaszynska A.
    J Hum Hypertens; 2008 Apr 09; 22(4):266-74. PubMed ID: 17928878
    [Abstract] [Full Text] [Related]

  • 11. Serum levels of the advanced glycation end products Nepsilon-carboxymethyllysine and pentosidine are not influenced by treatment with the angiotensin receptor II type 1 blocker irbesartan in patients with type 2 diabetic nephropathy and hypertension.
    Busch M, Franke S, Wolf G, Rohde RD, Stein G, Collaborative Study Group.
    Nephron Clin Pract; 2008 Apr 09; 108(4):c291-7. PubMed ID: 18434751
    [Abstract] [Full Text] [Related]

  • 12. Acteoside relieves mesangial cell injury by regulating Th22 cell chemotaxis and proliferation in IgA nephropathy.
    Gan L, Li X, Zhu M, Chen C, Luo H, Zhou Q.
    Ren Fail; 2018 Nov 09; 40(1):364-370. PubMed ID: 29708439
    [Abstract] [Full Text] [Related]

  • 13. ACE inhibitors and angiotensin II receptor blockers in IgA nephropathy with mild proteinuria: the ACEARB study.
    Pozzi C, Del Vecchio L, Casartelli D, Pozzoni P, Andrulli S, Amore A, Peruzzi L, Coppo R, Locatelli F, Adulto e Bambino Study Group, Immunopatologia Renale Study Group of the Italian Society of Nephrology.
    J Nephrol; 2006 Nov 09; 19(4):508-14. PubMed ID: 17048209
    [Abstract] [Full Text] [Related]

  • 14. Irbesartan in patients with atrial fibrillation.
    ACTIVE I InvestigatorsPopulation Health Research Institute, McMaster University, Hamilton, ON, Canada., Yusuf S, Healey JS, Pogue J, Chrolavicius S, Flather M, Hart RG, Hohnloser SH, Joyner CD, Pfeffer MA, Connolly SJ.
    N Engl J Med; 2011 Mar 10; 364(10):928-38. PubMed ID: 21388310
    [Abstract] [Full Text] [Related]

  • 15. Comparison of monotherapy with irbesartan 150 mg or amlodipine 5 mg for treatment of mild-to-moderate hypertension.
    Neutel JM, Germino FW, Smith D.
    J Renin Angiotensin Aldosterone Syst; 2005 Sep 10; 6(2):84-9. PubMed ID: 16470487
    [Abstract] [Full Text] [Related]

  • 16. Irbesartan for the treatment of hypertension in patients with the metabolic syndrome: a sub analysis of the Treat to Target post authorization survey. Prospective observational, two armed study in 14,200 patients.
    Kintscher U, Bramlage P, Paar WD, Thoenes M, Unger T.
    Cardiovasc Diabetol; 2007 Apr 03; 6():12. PubMed ID: 17407587
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of Shenyankangfu tablets for primary glomerulonephritis: study protocol for a randomized controlled trial.
    Kou J, Wu J, Yang HT, He YN, Fang JA, Deng YY, Xie YS, Nie LF, Lin HL, Cai GY, Chen XM.
    Trials; 2014 Dec 05; 15():479. PubMed ID: 25480673
    [Abstract] [Full Text] [Related]

  • 18. [Additive antiproteinuric effect of angiotensin II receptor antagonist and angiotensin-converting enzyme inhibitor in patients with chronic glomerulonephritis].
    Iimura O, Kusano E, Tanba K, Yanagiba S, Amemiya M, Ando Y, Honma S, Muto S, Asano Y.
    Nihon Jinzo Gakkai Shi; 2003 Jul 05; 45(5):439-44. PubMed ID: 14509219
    [Abstract] [Full Text] [Related]

  • 19. I-ADD study: assessment of efficacy and safety profile of irbesartan/amlodipine fixed-dose combination therapy compared with irbesartan monotherapy in hypertensive patients uncontrolled with irbesartan 150 mg monotherapy: a multicenter, phase III, prospective, randomized, open-label with blinded-end point evaluation study.
    Bobrie G, I-ADD Study Investigators.
    Clin Ther; 2012 Aug 05; 34(8):1720-34.e3. PubMed ID: 22853847
    [Abstract] [Full Text] [Related]

  • 20. [Role of mitochondrial autophagy and the curative effect of rehmannia glutinosa leaves total glycoside capsules on nucleos(t)ide drug-induced renal injury].
    Zhong K, Zhang MM, Zhu ZX, Liao X, Zhang BF, Cheng ML.
    Zhonghua Gan Zang Bing Za Zhi; 2024 Feb 20; 32(2):125-132. PubMed ID: 38514261
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.